Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation

SIMPLE SUMMARY: The anti-tumor role of Fasudil in EGFR-mutation NSCLC as well as its mechanism are largely unknown. Here, we show that Fasudil could effectively inhibit EGFR-mutation cell growth and enhance the sensitivity of gefitinib-resistant NSCLC cells to gefitinib by suppressing intracellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Tingting, Deng, Jingjing, Chen, Wenjuan, Xu, Juanjuan, Yang, Guanghai, Zhou, Mei, Lv, Zhilei, Wang, Sufei, Song, Siwei, Tan, Xueyun, Yin, Zhengrong, Li, Yumei, Jin, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563767/
https://www.ncbi.nlm.nih.gov/pubmed/36230634
http://dx.doi.org/10.3390/cancers14194709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563767/
https://www.ncbi.nlm.nih.gov/pubmed/36230634
http://dx.doi.org/10.3390/cancers14194709

Ejemplares similares